Floatz logo

64 assets in Esophageal Squamous Cell Carcinoma

Therapeutic assets addressing Esophageal Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Sigvotatug Vedotin
Esophageal Squamous Cell Carcinoma
Seagen, a wholly owned subsidiary of PfizerP1CC (42)
Abbv-400
Esophageal Squamous Cell Carcinoma
AbbVieP1C (39)
Evolve104
Esophageal Squamous Cell Carcinoma
EvolveImmune United, IncP1C (39)
ide034
Esophageal Squamous Cell Carcinoma
IDEAYA BiosciencesP1C (39)
Itraconazole
Esophageal Squamous Cell Carcinoma
AbbVieP1C (39)
mt-8421
Esophageal Squamous Cell Carcinoma
Molecular Templates, Inc.P1C (39)
pf-08046054
Esophageal Squamous Cell Carcinoma
Seagen, a wholly owned subsidiary of PfizerP1C (39)
pf-08046876
Esophageal Squamous Cell Carcinoma
PfizerP1C (39)
Plx-61639
Esophageal Squamous Cell Carcinoma
Plexium, Inc.P1C (39)
prt7732
Esophageal Squamous Cell Carcinoma
Prelude TherapeuticsP1C (39)
qeq278
Esophageal Squamous Cell Carcinoma
Novartis PharmaceuticalsP1C (39)
rad301
Esophageal Squamous Cell Carcinoma
Radiopharm Theranostics, LtdP1C (39)
Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda)
Esophageal Squamous Cell Carcinoma
SanofiP2C (33)
Volrustomig
Esophageal Squamous Cell Carcinoma
AstraZenecaP2NR ()
Showing 51 to 64 of 64 assets
PreviousPage 2 of 2Next